BioPharma Dive Published Online: July 18, 2022 Read the Full Article>> Identifying patients ‘outside the clinic’ can provide significant benefits for researchers and population health managers. Better understanding of patient cohorts can shed light on patient journeys, help optimize decisions around treatment choice and timing and inform the development of new therapies and intervention programs.[…]
Sage Journals Published June 22, 2022 Read the Full Manuscript>> Abstract Background Disability assessment using the Expanded Disability Status Scale (EDSS) is important to inform treatment decisions and monitor the progression of multiple sclerosis. Yet, EDSS scores are documented infrequently in electronic medical records. Objective To validate a machine learning model to estimate EDSS scores[…]
Read the Press Release >> BOSTON, June 23, 2022 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by[…]
First Published June 22, 2022 – Multiple Sclerosis Journal Assessment of multiple sclerosis (MS) disease activity is critical for understanding treatment effectiveness, informing treatment decisions, and monitoring disease progression. Magnetic resonance imaging (MRI) findings, clinician-administered assessments, and patient questionnaires are used to measure disease activity and track changes over time. The Expanded Disability Status Scale[…]
BioPharma Dive Online Read the Full Article>> Health inequities around the world produce disparities of a shocking magnitude. For example, life expectancy from birth ranges from approximately 55 to 85 years old depending on the country in which a child is born. Linked with degrees of social disadvantage, these same profound differences can be seen[…]
